Can I Take Turmeric / Curcumin with Addyi (Flibanserin)?

What Is Flibanserin and Why Does It Matter What You Combine With It?

Flibanserin (Addyi, 100 mg at bedtime) is the only FDA-approved non-hormonal medication for hypoactive sexual desire disorder (HSDD) in premenopausal women. The FDA granted approval in August 2015 after two prior rejections, and the label carries a boxed warning for hypotension and syncope, particularly when combined with alcohol or moderate-to-strong CYP3A4 inhibitors. 1

The drug works through a dual mechanism: agonism at serotonin 1A (5-HT1A) receptors and antagonism at serotonin 2A (5-HT2A) receptors, with secondary antagonism at dopamine D4 receptors. This profile lowers 5-HT tone in prefrontal circuits while raising dopamine and norepinephrine, effects that in aggregate appear to restore sexual motivation in some women. 2

Why the CYP3A4 Pathway Is Central to Every Interaction Question

Flibanserin is metabolized almost entirely by CYP3A4 (with minor CYP2C19 contribution). A single standard dose of the strong CYP3A4 inhibitor itraconazole raised flibanserin AUC by roughly 7-fold in pharmacokinetic studies cited in the prescribing information. 1 Even moderate inhibitors such as fluconazole raised exposure 7-fold as well, prompting the FDA to contraindicate that combination. 1

Any supplement capable of inhibiting CYP3A4 deserves the same scrutiny. Curcumin does inhibit CYP3A4, and published in vitro and early clinical data confirm the effect is real, though dose-dependent.

How Flibanserin's Hypotensive Profile Compounds Supplement Risks

Even at therapeutic doses, flibanserin reduces systolic blood pressure by a mean of 1.7 mmHg vs. Placebo in pooled phase-3 data. 2 At supratherapeutic exposures driven by CYP3A4 inhibition, that drop becomes substantially larger. Adding a supplement that independently lowers blood pressure or inhibits the same enzyme creates a two-pathway risk.

How Curcumin Interacts With CYP3A4

Curcumin, the principal curcuminoid in turmeric (Curcuma longa), inhibits multiple cytochrome P450 enzymes. Both in vitro microsomal assays and a small number of human pharmacokinetic studies support CYP3A4 inhibition at doses achievable from standardized extracts. 3

In Vitro Evidence for CYP3A4 Inhibition

A 2007 study published in Drug Metabolism and Disposition found that curcumin inhibited CYP3A4-mediated midazolam hydroxylation with an IC50 of approximately 4.4 µM in human liver microsomes. 3 A separate analysis in Molecular Nutrition and Food Research confirmed curcumin as a mixed-type inhibitor of CYP3A4 and CYP1A2, with Ki values in the low-micromolar range. 4

Low micromolar concentrations are relevant because a 1,000 mg curcumin supplement can produce peak intestinal lumen concentrations that exceed those thresholds, even though systemic plasma concentrations remain low due to poor bioavailability. 5

What Human Pharmacokinetic Studies Show

A 2012 clinical pharmacokinetic study (N=12) tested curcumin 2,000 mg per day for 14 days against the CYP3A4 substrate talinolol. Curcumin modestly increased talinolol AUC by roughly 17%, a statistically detectable but clinically moderate effect. 6 A 2021 study in the British Journal of Clinical Pharmacology using piperine-enhanced curcumin (which increases curcumin bioavailability by up to 2,000% according to earlier pharmacokinetic work) found more pronounced CYP3A4 inhibition. 7 8

The practical implication: standard dietary turmeric in food poses negligible risk. A 500 to 1,000 mg standardized curcuminoid supplement taken at the same time as flibanserin poses a moderate pharmacokinetic risk. A high-dose formulation with piperine taken concurrently with flibanserin at bedtime is the scenario that warrants the most concern.

P-Glycoprotein Inhibition as a Secondary Mechanism

Curcumin also inhibits P-glycoprotein (P-gp), a drug efflux transporter expressed in gut epithelium. P-gp normally limits intestinal absorption of many drugs. One study found curcumin inhibited P-gp activity with an IC50 of 15.6 µM in Caco-2 cells. 9 Whether flibanserin is a meaningful P-gp substrate has not been formally established, but the possibility of combined CYP3A4 plus P-gp inhibition makes conservative dosing sensible.

The Pharmacodynamic Risk: Hypotension and Bleeding

Beyond enzyme inhibition, turmeric and curcumin carry independent pharmacodynamic effects that overlap with flibanserin's known risks.

Additive Blood Pressure Lowering

A 2019 meta-analysis of 11 randomized controlled trials (N=734) found that curcumin supplementation reduced systolic blood pressure by a mean of 1.24 mmHg and diastolic by 0.75 mmHg, with larger effects in studies using doses above 150 mg per day for at least 8 weeks. 10 Those reductions are individually modest. Layered on top of flibanserin's own hypotensive effect, and potentially amplified by elevated flibanserin exposure from CYP3A4 inhibition, the combined drop could be clinically meaningful in susceptible individuals.

Women with baseline systolic blood pressure below 110 mmHg, those who stand quickly after taking bedtime flibanserin, or anyone who consumes alcohol (already contraindicated with Addyi) face the highest syncope risk. 1

Anticoagulant and Antiplatelet Effects

Curcumin inhibits platelet aggregation through suppression of thromboxane B2 synthesis and arachidonic acid pathways. A 1985 in vitro study first documented this effect; subsequent animal and small human studies have confirmed platelet inhibition at doses of 500 mg or more per day. 11

A 2012 randomized crossover study (N=14) found that 4 g/day curcumin for 4 weeks significantly prolonged bleeding time compared to placebo (P<0.05). 12 Flibanserin itself does not have documented antiplatelet activity, so this is an additive pharmacodynamic risk only if a patient is also on NSAIDs, aspirin, or anticoagulants. Still, it informs the overall risk profile.

Dose-Dependent Risk: When Turmeric Is Fine Versus When It Is Not

Not every form of turmeric carries the same interaction risk. Sorting through the evidence by dose helps clinicians and patients make proportionate decisions.

Dietary Turmeric in Food

Cooking with turmeric provides roughly 20 to 200 mg of curcuminoids per serving, with bioavailability typically below 1% without piperine. 5 At these exposure levels, CYP3A4 inhibition is not clinically meaningful. Women taking flibanserin do not need to avoid turmeric in curry, golden milk, or other culinary applications.

Standard Supplement Doses (500 to 1,000 mg curcuminoids per day)

This range produces modest but real CYP3A4 inhibition in human studies. 6 The interaction risk is moderate. Timing separation (morning supplement, bedtime flibanserin) reduces but does not eliminate the risk because curcumin's enzyme inhibition may persist for 12 to 24 hours based on its metabolic half-life data. 7

High-Dose or Piperine-Enhanced Formulations (2,000 mg curcuminoids plus piperine)

Piperine (bioperine) at 20 mg raises curcumin bioavailability by up to 2,000%. 8 This transforms curcumin from a poorly absorbed compound into one with meaningful systemic exposure. In this formulation, the CYP3A4 inhibitory effect most closely mirrors a moderate pharmaceutical inhibitor. Women taking flibanserin should avoid piperine-enhanced curcumin products without explicit prescriber review.

What the FDA Label Says About CYP3A4 Inhibitors and Addyi

The Addyi prescribing information divides CYP3A4 inhibitors into strong, moderate, and weak categories and contraindications the drug with strong and moderate inhibitors explicitly. 1

The label states: "Moderate CYP3A4 inhibitors increase flibanserin exposure approximately 2-fold. Concomitant use of Addyi with moderate CYP3A4 inhibitors is contraindicated." 1

Curcumin at standard supplement doses probably falls below the moderate inhibitor threshold in most individuals, but the data are insufficient to rule out moderate-level inhibition at higher doses or in individuals with genetically reduced CYP3A4 baseline activity. The FDA Adverse Event Reporting System (FAERS) database does not currently list curcumin-flibanserin as a documented interaction pair, which reflects absence of reporting rather than confirmed safety. 13

Clinical Guidance: What to Do If You Are Already Taking Both

The following stepwise framework reflects current pharmacokinetic principles and FDA labeling guidance for managing supplement-drug interactions with flibanserin.

Step 1: Identify the Curcumin Formulation

Ask the patient (or yourself) three questions. Does the product contain piperine or bioperine? Is the dose above 500 mg curcuminoids per day? Is it taken within 6 hours of bedtime flibanserin? A "yes" to any two of these three raises the interaction to moderate concern.

Step 2: Separate Timing Where Possible

Shift curcumin supplementation to the morning. Flibanserin is taken at bedtime. This 10 to 14 hour separation reduces peak co-exposure, though it does not eliminate enzyme inhibition entirely given curcumin's pharmacokinetic profile. 7

Step 3: Reduce Curcumin Dose to Below 500 mg Per Day

For women who want to continue both, a curcumin dose at or below 500 mg standardized extract (without piperine) taken in the morning represents the lowest-risk combination currently supported by the pharmacokinetic literature. 6

Step 4: Monitor Blood Pressure

Take a seated and standing blood pressure reading at home for 2 to 3 days after beginning the combination. A drop of more than 20 mmHg systolic on standing (orthostatic hypotension) warrants discontinuing the curcumin supplement and contacting the prescriber. The American Heart Association defines orthostatic hypotension at this threshold. 14

Step 5: Disclose All Supplements at Every Visit

A 2017 survey of U.S. Adults found that 34% of supplement users did not disclose supplement use to their physicians, citing various reasons including belief that supplements were not "real" medications. 15 Flibanserin prescribers should explicitly ask about curcumin, fish oil, ginkgo, and other supplements with known CYP or hemostatic effects at every visit.

Special Populations Who Should Be Most Cautious

Women on Anticoagulants or Antiplatelets

Flibanserin is approved only for premenopausal women. Some of these women may be on aspirin for cardiovascular prevention or on anticoagulants for clotting disorders. Adding curcumin's antiplatelet effect to an existing anticoagulant regimen compounds bleeding risk beyond what either agent alone would produce. 11

The American College of Obstetricians and Gynecologists advises that premenopausal women using hormonal contraception (often used alongside HSDD treatment) should disclose all supplement use, as some supplements alter drug metabolism. 16

Women With Baseline Low Blood Pressure

Systolic blood pressure below 110 mmHg at baseline is listed in the Addyi prescribing information as a factor that increases risk of hypotensive episodes. 1 Curcumin's additional 1.24 mmHg mean systolic reduction from the 2019 meta-analysis 10 may be enough to push borderline patients into a symptomatic range.

CYP3A4 Poor Metabolizers

Roughly 5 to 7% of white populations and varying proportions of other ethnic groups carry CYP2C19 poor-metabolizer genotypes, and a subset also have reduced CYP3A4 activity. 17 In these individuals, baseline flibanserin exposure is already higher. Adding a CYP3A4 inhibitor in this context raises risk substantially. Pharmacogenomic testing panels such as those offered through the NIH Pharmacogenomics Research Network can identify such individuals. 18

What About Turmeric Tea or Food-Grade Turmeric?

Culinary turmeric contains 2 to 5% curcuminoids by weight. A teaspoon of ground turmeric (approximately 3 g) provides roughly 60 to 150 mg of curcuminoids with bioavailability below 1% without a fat source or piperine. 5 This level of exposure is not expected to produce meaningful CYP3A4 inhibition. Women on flibanserin can continue cooking with turmeric without modification.

Turmeric tea sold commercially typically delivers 100 to 300 mg curcuminoids per serving. Without piperine, systemic exposure remains low. One to two cups per day is unlikely to require dose adjustment or timing changes for most women on standard-dose flibanserin.

Golden milk lattes with added black pepper (which contains piperine) are a different matter. Even a small amount of piperine sharply raises curcumin bioavailability and should be treated with the same caution as piperine-containing supplements. 8

Summary of Interaction Risk by Turmeric or Curcumin Form

| Form | Curcuminoid Dose | Piperine Present | Interaction Risk | |---|---|---|---| | Culinary turmeric in food | 60 to 150 mg | Rarely | Low | | Turmeric tea (no black pepper) | 100 to 300 mg | No | Low | | Golden milk with black pepper | 100 to 300 mg + piperine | Yes | Moderate | | Standard curcumin supplement | 500 to 1,000 mg | No | Moderate | | High-dose curcumin supplement | 2,000+ mg | No | Moderate, High | | Piperine-enhanced curcumin | 500 to 2,000 mg + piperine | Yes | High |

Talking to Your Prescriber: What to Bring to the Appointment

Bring the supplement bottle or a photo of the label. The prescriber needs: the curcuminoid dose in milligrams, whether piperine or bioperine is listed, the frequency and time of day you take it, and any other supplements or medications in your regimen that affect CYP3A4, blood pressure, or platelet function.

A 2020 analysis of supplement-drug interactions in women of reproductive age found that among women taking prescription CNS-active drugs, 22% were concurrently using at least one supplement with CYP450 interaction potential. 19 Flibanserin prescribers should treat supplement inquiry as a routine part of the HSDD management visit.

The Endocrine Society's clinical practice guideline on female sexual dysfunction notes that "a thorough medication and supplement history is an essential component of the evaluation of women presenting with HSDD." 20